uniQure N.V Revenue Growth & History (QURE)
uniQure N.V reported $16.1M in revenue for fiscal 2025, a decrease of 40.64% from the previous fiscal year.
View full uniQure N.V company overviewuniQure N.V annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $16.1M | −$11.0M | −40.64% |
| 2024 | 2024-12-31 | $27.1M | $11.3M | +71.17% |
| 2023 | 2023-12-31 | $15.8M | −$90.6M | −85.12% |
| 2022 | 2022-12-31 | $106.5M | −$417.5M | −79.68% |
| 2021 | 2021-12-31 | $524.0M | $486.5M | +1296.82% |
| 2020 | 2020-12-31 | $37.5M | $30.2M | +415.23% |
| 2019 | 2019-12-31 | $7.3M | −$4.0M | −35.48% |
| 2018 | 2018-12-31 | $11.3M | −$1.8M | −13.91% |
| 2017 | 2017-12-31 | $13.1M | −$12.0M | −47.78% |
| 2016 | 2016-12-31 | $25.1M | $14.5M | +137.27% |
| 2015 | 2015-12-31 | $10.6M | $4.4M | +72.25% |
| 2014 | 2014-12-31 | $6.1M | — | — |
uniQure N.V quarterly revenue
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.8M | $579,000 | +11.00% |
| Q1 2026 | 2026-03-31 | $3.6M | $2.0M | +127.31% |
| Q4 2025 | 2025-12-31 | $5.6M | $347,000 | +6.65% |
| Q3 2025 | 2025-09-30 | $3.7M | $1.4M | +61.83% |
| Q2 2025 | 2025-06-30 | $5.3M | −$5.9M | −52.71% |
| Q1 2025 | 2025-03-31 | $1.6M | −$6.9M | −81.53% |
| Q4 2024 | 2024-12-31 | $5.2M | −$1.5M | −21.95% |
| Q3 2024 | 2024-09-30 | $2.3M | $880,000 | +62.54% |
| Q2 2024 | 2024-06-30 | $11.1M | $8.7M | +359.37% |
| Q1 2024 | 2024-03-31 | $8.5M | $3.2M | +59.34% |
| Q4 2023 | 2023-12-31 | $6.7M | −$96.1M | −93.49% |
| Q3 2023 | 2023-09-30 | $1.4M | −$42,000 | −2.90% |
| Q2 2023 | 2023-06-30 | $2.4M | $1.9M | +387.32% |
| Q1 2023 | 2023-03-31 | $5.3M | $3.5M | +197.15% |
| Q4 2022 | 2022-12-31 | $102.7M | $45.1M | +78.10% |
| Q3 2022 | 2022-09-30 | $1.4M | −$540,000 | −27.15% |
| Q2 2022 | 2022-06-30 | $497,000 | −$463.4M | −99.89% |
| Q1 2022 | 2022-03-31 | $1.8M | $1.3M | +294.71% |
| Q4 2021 | 2021-12-31 | $57.7M | $23.6M | +69.25% |
| Q3 2021 | 2021-09-30 | $2.0M | $200,000 | +11.18% |
| Q2 2021 | 2021-06-30 | $463.9M | $462.3M | +30119.41% |
| Q1 2021 | 2021-03-31 | $454,000 | $350,000 | +336.54% |
| Q4 2020 | 2020-12-31 | $34.1M | $31.5M | +1198.51% |
| Q3 2020 | 2020-09-30 | $1.8M | $743,000 | +71.03% |
| Q2 2020 | 2020-06-30 | $1.5M | −$939,000 | −37.95% |
| Q1 2020 | 2020-03-31 | $104,000 | −$1.0M | −90.85% |
| Q4 2019 | 2019-12-31 | $2.6M | $1.0M | +63.25% |
| Q3 2019 | 2019-09-30 | $1.0M | −$2.1M | −66.77% |
| Q2 2019 | 2019-06-30 | $2.5M | −$576,000 | −18.89% |
| Q1 2019 | 2019-03-31 | $1.1M | −$2.3M | −67.34% |
| Q4 2018 | 2018-12-31 | $1.6M | −$976,000 | −37.77% |
| Q3 2018 | 2018-09-30 | $3.1M | $888,000 | +39.29% |
| Q2 2018 | 2018-06-30 | $3.0M | −$1.9M | −38.28% |
| Q1 2018 | 2018-03-31 | $3.5M | $157,000 | +4.73% |
| Q4 2017 | 2017-12-31 | $2.6M | −$6.5M | −71.70% |
| Q3 2017 | 2017-09-30 | $2.3M | −$5.0M | −68.70% |
| Q2 2017 | 2017-06-30 | $4.9M | $491,000 | +11.03% |
| Q1 2017 | 2017-03-31 | $3.3M | −$974,000 | −22.68% |
| Q4 2016 | 2016-12-31 | $9.1M | — | — |
| Q3 2016 | 2016-09-30 | $7.2M | — | — |
| Q2 2016 | 2016-06-30 | $4.5M | — | — |
| Q1 2016 | 2016-03-31 | $4.3M | — | — |
uniQure N.V revenue growth trends
Over the last five reported fiscal years, revenue declined from $37.5M to $16.1M, a compound annual decline of 15.57%. uniQure N.V's latest reported quarter, Q2 2026, generated $5.8M in revenue, an increase of 11.00% year over year.
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review uniQure N.V source filings ↗Community posts
uniQure reports longer Huntington’s follow-up, with mixed statistical results
uniQure ($QURE) released additional Phase I/II results for AMT-130 in Huntington’s disease. Among 15 high-dose patients followed for 36 months, the company reported 80% slower decline on the composite disease-rating scale against an externa ...